Software as a Medical Service Changes the Reimbursement Conversation

Stage capital against payment uncertainty.

I would treat the proposed payment category as an option whose value depends on unresolved policy and operating conditions. Category recognition, a usable code, coverage, payment amount, provider adoption and retained margin are separate steps. A forecast should show where each assumption enters and which costs become committed before it is resolved.

The underlying service should be defined independently of the hoped-for payment. What decision changes, who is accountable for it and what would the care team do without the software? This counterfactual matters because an algorithm can add a billable activity while duplicating existing work or generating downstream services of uncertain value. The purchaser needs evidence of incremental clinical or operational contribution, not just evidence that the computation occurred.

For a provider, I would model contribution after clinician review, documentation, integration, claim work and the cost of failed collection. For the payer, I would evaluate the new service payment alongside changes elsewhere in the episode. For the vendor, I would test whether its price leaves a viable delivery model for the institution using it. These ledgers can move in different directions; a new revenue stream is not itself evidence of a better total-cost outcome.

The product roadmap should preserve commercially plausible alternatives while the proposal remains unresolved: enterprise purchase, inclusion in an existing service or a specific payer arrangement, where appropriate. Each alternative has its own requirements and should be underwritten separately. I would defer irreversible expansion whose only viable return depends on a proposed payment assumption, while funding the evidence and workflow capabilities useful across credible routes.